ProCE Banner Activity

CME

Prostate Cancer Master Class: Addressing Challenges in a New Era of Personalized Care

Video

Watch this on-demand webcast from a June 2023 symposium featuring Matthew R. Smith, MD, PhD; Alan H. Bryce, MD; Tanya B. Dorff, MD; Karim Fizazi, MD, PhD; Xin Gao, MD; and Rana R. McKay, MD, on recognizing and managing the emerging challenges to individualize therapy for patients with prostate cancer.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 21, 2023

Expiration: June 20, 2024

Share

Faculty

Alan H. Bryce

Alan H. Bryce, MD

Chief Clinical Officer
Professor, Department of Medical Oncology and Therapeutics Research 
Professor of Molecular Medicine, TGEN
City of Hope
Phoenix, Arizona

Tanya B. Dorff

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Karim Fizazi

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

Xin Gao

Xin Gao, MD

Assistant Professor of Medicine
Harvard Medical School
Medical Oncologist
Medicine-Hematology/Oncoloy
Massachusetts General Hospital
Boston, Massachusetts

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Matthew R. Smith

Matthew R. Smith, MD, PhD

Professor of Medicine
Harvard Medical School
Director
Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with prostate cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners on recognizing and managing the emerging challenges to individualize therapy for patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply expert recommendations for testing for clinically relevant biomarkers and using advanced molecular imaging to guide treatment strategies in patients with prostate cancer

  • Plan optimal individualized therapeutic strategies for nonmetastatic or metastatic hormone-sensitive prostate cancer (HSPC), considering available agents, clinical data, expert recommendations, and individual patient needs and preferences

  • Employ an evidence-based approach to the selection and sequencing of available options for patients with mCRPC (including the use of PARP inhibitors alone or with secondary hormonal therapies and the PSMA-targeted radioligand therapy for progressive PSMA-positive mCRPC)

  • Proactively mitigate and manage treatment-related AEs in patients receiving novel therapies and combinations for advanced prostate cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Alan H. Bryce, MD

Chief Clinical Officer
Professor, Department of Medical Oncology and Therapeutics Research 
Professor of Molecular Medicine, TGEN
City of Hope
Phoenix, Arizona

Alan Bryce, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Janssen, Merck, Myovant, Novartis, Pfizer; researcher: Janssen.

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Tanya B. Dorff, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Janssen, Sanofi.

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

Karim Fizazi, MD, PhD: advisory board: Amgen, Arvinas, Astellas, AstraZeneca, Bayer, Clovis, CureVac, Daiichi Sankyo, Janssen, Macrogenics, MSD, Novartis/AAA, Orion, Pfizer, Sanofi.

Xin Gao, MD

Assistant Professor of Medicine
Harvard Medical School
Medical Oncologist
Medicine-Hematology/Oncoloy
Massachusetts General Hospital
Boston, Massachusetts

Xin Gao, MD: consultant/advisor/speaker: Bayer, Flare, Guardant, Myovant, PathAI, PureTech Health, Silverback.

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Eisai, Johnson & Johnson, Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus.

Matthew R. Smith, MD, PhD

Professor of Medicine
Harvard Medical School
Director
Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Matthew R. Smith, MD, PhD: consultant/advisor/speaker: Bayer, Janssen, Lilly, Pfizer.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 21, 2023, through June 20, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.